Guidelines for Administering Gadolinium-Based Contrast Agents in Patients with Renal Dysfunction (2024 Revision)

Journal Club Presentation

Clinical and Experimental Nephrology (2025)

Mentor: Dr.Ghorbani

Presented by: Hoda Vahedi, Neda Fatholahzadeh

Introduction

- Nephrogenic systemic fibrosis (NSF): rare, serious complication after GBCA exposure
- Causes: skin thickening, pain, limb contractures, disability
- High mortality in severe cases
- Initial guideline: 2008, revised 2009 → current update: May 2024

Why is this Guideline Important?

- GBCAs essential for MRI contrast but risk of NSF in CKD/AKI patients
- Balance between diagnostic benefit vs safety concerns
- Need for updated recommendations with latest evidence

Key Recommendations

1. Use GBCAs only when absolutely necessary

2. Evaluate renal function (eGFR) before contrast MRI (unless emergency)

3. Prefer alternatives in:

- Dialysis patients
- CKD with eGFR <30 ml/min/1.73m²
- Acute kidney injury

4. If unavoidable → use lowest-risk GBCA, space doses ≥7 days

Key Reasons for Revision

- GBCAs work by binding gadolinium; unstable chelates linked to NSF are no longer sold in Japan(Table 1).
- NSF risk extremely low with current Japan-approved agents, even in severe CKD/dialysis.

Table 1 – GBCAs sold in Japan (including those no longer commercially available)

Contrast agent	Abbreviation	Trade name	Comments
Gadoteridol	Gd-HP-DO3A	Prohance	
Gadoterate	Gd-DOTA	Magnescope	
Gadobutrol	Gd-BT-DO3A	Gadovist	
Gadoxetate sodium	Gd-EOB-DTPA	EOB, Primovist	Liver-specific contrast agent
Gadodiamide	Gd-DTPA-BMA	Omniscan	Currently unavailable
Gadopentetate	Gd-DTPA	Magenvist	Currently unavailable

Updates from Previous Guideline

- Old: strict avoidance in ESRD, CKD <30, AKI
- New: avoidance is preferable, but GBCA may be used cautiously if alternatives not possible
- Emphasis on individual risk-benefit assessment

Supporting Evidence

- Woolen et al. (meta-analysis, 16 studies): No NSF with group II GBCAs
- Amet et al.: No NSF among 287 dialysis patients with stable agents
- Alfano et al.: 344 dialysis patients, 0 cases of NSF with Gadoterate
- Michaely et al.: 908 CKD patients (incl. stage 4/5), no NSF
- Starekova et al.: 7820 exams, no NSF (Gadoxetic acid)
- Attari et al.: (systematic review): Only 1 NSF case with stable GBCAs

Comparison with International Guidelines

- ESUR (Europe): caution if eGFR <30; 7 days between doses
- ACR (US): contrast-enhanced CT preferred in dialysis; if MRI → use Group II GBCAs
- Japanese guideline aligns but emphasizes patient-specific decision-making

Strengths and Limitations

Strengths:

- Incorporates latest meta-analyses & global data
- Practical recommendations for clinicians

Limitations:

- Primarily based on observational studies
- Few data in CKD stage 5 non-dialysis patients
- Need for long-term follow-up studies

Clinical Takeaways

- GBCAs safe in most CKD patients if stable agents used
- Avoid if eGFR <30 or dialysis, unless absolutely necessary
- Always consider alternatives, minimize repeat doses
- Individualize decision based on risk-benefit

Discussion Points

- How does this guideline change local practice?
- Should contrast-enhanced CT be prioritized over MRI in advanced CKD?
- What monitoring is needed post-GBCA exposure in high-risk patients?